{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:13Z","timestamp":1793091253010,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation-Joint Fund of Original Innovation of Haidian","award":["L202040"],"award-info":[{"award-number":["L202040"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Both adaptive and innate immunity responses are necessary for the efficient elimination of different pathogens. However, the magnitude, quality and desired type of immune response specific to the co-administered antigen is largely determined by adjuvants. BC02 (BCG CpG DNA compound adjuvants system 02) is a novel compound adjuvant with independent intellectual properties, which is composed of BCG CpG DNA biological adjuvant with Al(OH)3 inorganic salt adjuvant acting as a delivery system. Its safety and strong adjuvant efficacy have been effectively verified in preclinical and clinical trials (Phase Ib, ClinicalTrials.gov Identifier: NCT04239313 and Phase II, ClinicalTrials.gov Identifier: NCT05284812). In this study, we report the level of cell-mediated immunity (CMI) and humoral immune response induced by the BC02 novel adjuvant combined with different doses of varicella-zoster virus (VZV) glycoprotein E (gE) in a mouse model. In addition, we conducted preliminary in vitro experiments to explore the enhancement of RAW264.7 cell immune activity by BC02 adjuvanted-gE experimental vaccine to activate innate immune response. The results showed that the BC02-adjuvanted low, medium or high dose of gE were highly effective in eliciting both CMI and humoral immune responses to the immunized mice, respectively. The production of gE-specific IFN-\u03b3 and IL-2-specific T cells was established within 28 days after booster immunization. In particular, the effect of BC02-adjuvanted medium dose of gE has been shown to be more prominent. Meanwhile, fluorescent antibody to membrane antigen (FAMA) and serum antibody plaque reduction tests have also shown that the BC02 adjuvanted-medium dose of gE antigen could induce the secretion of neutralizing antibodies against clinically isolated VZV strains in mice. In addition, our findings have shown that 1\/25 dose of gE+BC02 medium dose experimental vaccine can significantly induce the secretion of innate immune cytokines TNF-A, MCP-1, IL-6 and GM-CSF and up-regulate the costimulatory molecules CD40, CD80 and I-A\/I-E on RAW264.7 cells; and it has also been activated to form M2 macrophages. At the same time, RAW264.7 cells were stimulated for 12 h, and their phagocytosis was significantly enhanced. Taken together, these results suggest that the BC02 compound adjuvant offers a strategy to induce an appropriate innate and adaptive immunity against the different doses of the VZV gE protein to improve subunit vaccine efficacy, and BC02 may be a promising adjuvant candidate for subunit HZ vaccines.<\/jats:p>","DOI":"10.3390\/vaccines10122155","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:16:41Z","timestamp":1671157001000},"page":"2155","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Novel BC02 Compound Adjuvant Enhances Adaptive and Innate Immunity Induced by Recombinant Glycoprotein E of Varicella-Zoster Virus"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-3375","authenticated-orcid":false,"given":"Junli","family":"Li","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China"},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Fu","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China"},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Guo","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China"},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China"},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Vaccine and Allergen Products, Institute of Biological Product Control, National Institutes for Food and Drug Control, Beijing 102629, China"},{"name":"Key Laboratory for Quality Research and Evaluation of Biological Products, National Medical Products Administration (NMPA), Beijing 102629, China"},{"name":"Key Laboratory of Research on Quality and Standardization of Biotech Products, National Health Commission (NHC), Beijing 102629, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: Formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J. Clin. Investing"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3389\/fimmu.2018.02874","article-title":"Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?","volume":"9","author":"Ho","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1753425919879997","article-title":"Unmethylated CpG motif-containing genomic DNA fragment of Bacillus calmette-guerin promotes macrophage functions through TLR9-mediated activation of NF-\u03baB and MAPKs signaling pathways","volume":"26","author":"Li","year":"2020","journal-title":"Innate Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccines"},{"key":"ref_8","first-page":"1493","article-title":"Durability and Immunogenicity of Neutralizing Antibodies Response against Omicron Variants after Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study","volume":"11","author":"Hsieh","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S2213-2600(21)00402-1","article-title":"Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: Interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan","volume":"9","author":"Hsieh","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: A phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen\u00ae, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1574-695X.2010.00660.x","article-title":"The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants","volume":"59","author":"Chen","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_13","first-page":"1177","article-title":"Immune effect of STAg combined with BCG-DNA and aluminum hydroxide adjuvant in mice","volume":"24","author":"Zhang","year":"2011","journal-title":"Chin. J. Biol."},{"key":"ref_14","first-page":"941","article-title":"Synergistic enhancement of macrophage innate immune response with BC02 complex adjuvant","volume":"31","author":"Li","year":"2018","journal-title":"Chin. J. Biol."},{"key":"ref_15","first-page":"11","article-title":"Analysis of synergistic enhancement of innate immune response by BC02 compound adjuvant components","volume":"35","author":"Li","year":"2022","journal-title":"Chin. J. Biol."},{"key":"ref_16","first-page":"524","article-title":"Analysis of Koch phenomenon of Mycobacterium tuberculosis-infected guinea pigs vaccinated with recombinant tuberculosis vaccine AEC\/BC02","volume":"39","author":"Lu","year":"2016","journal-title":"Chin. J. Tuberc. Respir."},{"key":"ref_17","first-page":"414","article-title":"Therapeutic evaluation of antibiotics combined with recombinant tuberculosis vaccine AEC\/BC02 in a guinea pig model of Mycobacterium tuberculosis infection","volume":"38","author":"Lu","year":"2018","journal-title":"Chin. J. Microbiol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lu, J., Guo, X., Wang, C., Du, W., Shen, X., Su, C., Wu, Y., and Xu, M. (2022). Therapeutic Effect of Subunit Vaccine AEC\/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model. Vaccines, 10.","DOI":"10.3390\/vaccines10050825"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"European Medicines Agency (2016, March 14). Zostavax [shingles (herpes zoster) vaccine (live)]: EU Summary of Product Characteristics. Available online: http:\/\/www.ema.europa.eu\/."},{"key":"ref_21","first-page":"1","article-title":"Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/M17-3439","article-title":"Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018","volume":"168","author":"Kim","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/JVI.00913-08","article-title":"Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry","volume":"83","author":"Berarducci","year":"2009","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0912373107","article-title":"Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection","volume":"107","author":"Berarducci","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives","volume":"6","author":"Chomez","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0264-410X(02)00556-X","article-title":"Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production","volume":"21","author":"Iyer","year":"2003","journal-title":"Vaccines"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.vaccine.2004.01.061","article-title":"Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type","volume":"22","author":"Rimaniol","year":"2004","journal-title":"Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: Current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","article-title":"Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine","volume":"12","author":"Fochesato","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archinte.1982.00340150091016","article-title":"Immune responses to varicella-zoster in the aged","volume":"142","author":"Burke","year":"1982","journal-title":"Arch. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcv.2012.06.008","article-title":"A community-based survey of varicella-zoster virus-specific immune responses in the elderly","volume":"55","author":"Tang","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: The SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/infdis\/139.4.432","article-title":"Complement-enhanced neutralizing antibody response to varicella-zoster virus","volume":"139","author":"Grose","year":"1979","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccines"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ofy118","DOI":"10.1093\/ofid\/ofy118","article-title":"Cellular Stress Response to Varicella-Zoster Virus Infection of Human Skin Includes Highly Elevated Interleukin-6 Expression","volume":"Volume 5","author":"Jarosinski","year":"2018","journal-title":"Open Forum Infectious Diseases"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:56Z","timestamp":1760146916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122155"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122155","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}